お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
987752

BiTE抗体の世界市場:価格、販売、臨床試験インサイト(2025年)

Global BiTE Antibodies Market , Price, Sales & Clinical Trials Insight 2025

出版日: | 発行: KuicK Research | ページ情報: 英文 100 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=107.25円

ご注意: DRM (デジタル著作権管理システム) 付PDFになります。制限内容はお問合せください。
Multi-User License: 会社全体での使用権

BiTE抗体の世界市場:価格、販売、臨床試験インサイト(2025年)
出版日: 2021年02月10日
発行: KuicK Research
ページ情報: 英文 100 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のBiTE抗体市場は、数百社ものバイオ製薬企業や研究センターが、より強力な医薬品の商業的使用の承認による拡大に関与しており、市場全体が世界レベルで急速に成熟すると見られています。同市場は何百万人もの患者のための標準的かつ支配的な治療計画として認識されるようになると予測されています。

当レポートは、世界のBiTE抗体市場について調査しており、市場機会や動向、販売分析、フェーズ・企業・国・適応症・患者セグメント別の臨床試験指標、市場力学、競合情勢、主要企業のプロファイルなどの情報を提供しています。

目次

第1章 二重特異性抗体:次世代抗体療法

  • 二重特異性抗体の歴史
  • 二重特異性抗体の概要

第2章 モノクローナル抗体に対する二重特異性抗体の利点

第3章 BiTE(Bispecific T Cell Engager):癌免疫療法の新時代

第4章 BiTEの構造と設計

  • 単鎖可変領域フラグメント(scFv)抗体の構築
  • 二重特異性scFv抗体の発現と産生

第5章 BiTE抗体:作用機序

  • BiTEによりリダイレクトされた標的細胞溶解
  • BiTEによるT細胞の活性化
  • BiTEによる溶解性シナプス形成

第6章 ブリナツモマブ(Blincyto):最初に承認されたBiTE抗体

  • 臨床試験、承認および特許取得
  • 設計と作用機序
  • 副作用と管理

第7章 世界のBiTE抗体臨床試験指標

  • フェーズ別
  • 企業別
  • 国別
  • 適応症別
  • 患者セグメント別

第8章 企業別:世界のBiTE臨床パイプライン、適応症およびフェーズ

  • 前臨床
  • フェーズI

第9章 世界のBiTE抗体市場概要

  • 現在の市場シナリオ
  • Blincytoの償還方針

第10章 Blincyto:投与量と市場販売の分析

  • B-ALLにおけるBlincytoの投与量
  • 現在の市場販売分析

第11章 二重特異性T細胞エンゲージメントの臨床パイプライン

第12章 T細胞と腫瘍の橋渡し:CARとBiTE

第13章 BiTE:進行中の研究開発

  • 再発・難治性多発性骨髄腫に対するBiTeベースの免疫療法治療
  • 新規DLL3ターゲットBiTE:小細胞肺癌で抗腫瘍活性を示す
  • 転移性去勢におけるAMG160の予備的有効性:耐性前立腺癌

第14章 世界のBiTE市場力学

  • 有利な市場パラメータ
  • 商品化の課題

第15章 世界のBiTE市場の将来の見通し

第16章 競合情勢

  • Amgen
  • Bayers
  • Micromet
  • Psioxus Therapeutics
  • Y Biologics
図表

List of Figures

  • Figure 1-1: Evolution of Bispecific Antibodies
  • Figure 1-2: Bispecific Antibodies Structure
  • Figure 1-3: Formats of Bispecific Antibodies
  • Figure 2-1: Advantages of Bispecific Antibody over Monoclonal Antibody
  • Figure 3-1: Structure of Bispecific T-Cell Engagers
  • Figure 3-2: General Mechanism of BiTE
  • Figure 4-1: Construction of scFv Antibodies
  • Figure 4-2: Antibodies Expression & Production in E. coli
  • Figure 4-3: Expression & Production of Antibodies in CHO System
  • Figure 4-4: Various Expression Systems for Antibodies
  • Figure 5-1: Redirected Target T Cell Lysis
  • Figure 5-2: Synapse Formation by BiTE
  • Figure 6-1: Blincyto - FDA Approval Year by Indication
  • Figure 6-2: History of Clinical Trials
  • Figure 6-3: Blincyto - Patent Approval & Expires Year
  • Figure 6-4: Design of Blinatumomab
  • Figure 6-5: Mechanism of Action of Blinatumomab
  • Figure 7-1: Global - BiTE Antibody Clinical Trials by Phase, 2020 -2025
  • Figure 7-2: Global - BiTE Antibody Clinical Trials by Company, 2020 -2025
  • Figure 7-3: Global - BiTE Antibody Clinical Trials by Country, 2020 -2025
  • Figure 7-4: Global - BiTE Antibody Clinical Trials by Indication, 2020 -2025
  • Figure 7-5: Global - BiTE Antibody Clinical Trials by Patient Segment, 2020 -2025
  • Figure 9-1: Global - BiTE Under Development
  • Figure 9-2: Global - BiTE Market (US$ Million), 2016-2020
  • Figure 9-3: US - BiTE Market (US$ Million), 2016-2020
  • Figure 9-4: Global (Excluding US) - BiTE Market (US$ Million), 2016-2020
  • Figure 9-5: Global - BiTE Market Growth Rate (CAGR %), 2016-2020
  • Figure 9-6: Global - BiTE Market Future Estimates (US$ Million), 2021 - 2025
  • Figure 9-7: Global - Avastin & Herceptin Market (US$ Billion), 2017-2019
  • Figure 9-8: Blincyto - Total Treatment Cost & Reimbursement
  • Figure 9-9: Blincyto - In Pocket & Out of Pocket Expenditure
  • Figure 10-1: Induction & Consolidation Cycles in MRD +ve B-ALL
  • Figure 10-2: Treatment Interval (weeks) Per Cycle
  • Figure 10-3: Induction, Consolidation & Continued Therapy Cycles in R/R B-ALL
  • Figure 10-4: Blincyto - Recommended Dose for R/R B-ALL
  • Figure 10-5: Global - Blincyto Quarterly Sales by Region (US$ Million), Q1'2019
  • Figure 10-6: Blincyto - Quarterly Sales by Region (%), Q1'2019
  • Figure 10-7: Global - Blincyto Quarterly Sales (US$ Million), Q1'2018 & Q1'2019
  • Figure 10-8: Global - Blincyto Sales by Region (US$ Million) Q2'2019
  • Figure 10-9: Global - Blincyto Sales (US$ Million), Q2'2018 & Q2'2019
  • Figure 10-10: Global - Blincyto Sales by Region (US$ Million), Q3'2019
  • Figure 10-11: Global - Blincyto Sales by Region (%), Q3'2019
  • Figure 10-12: Global - Blincyto Sales (US$ Million), Q3'2018 & Q3'2019
  • Figure 10-13: Global - Blincyto Sales by Region (US$ Million), Q4'2019
  • Figure 10-14: Blincyto -Sales Value by Region (%), Q4'2019
  • Figure 10-15: Global - Blincyto Sales (US$ Million), Q4'2018 & Q4'2019
  • Figure 10-16: Global - Blincyto Sales (US$ Million), 2017 - 2020
  • Figure 10-17: Global - Blincyto Sales by Region (%), Q1'2020
  • Figure 10-18: Global - Blincyto Sales by Region (%), Q2'2020
  • Figure 10-19: Global - Blincyto Sales by Region (%), Q3'2020
  • Figure 10-20: Global - Blincyto Sales by Region (%), Q4'2020
  • Figure 10-21: Global - Blincyto Sales (US$ Millions), Q1'2020 - Q4'2020
  • Figure 11-1: BiTE in Clinical Trials
  • Figure 11-2: Combinational Therapies with Blincyto in Clinical Trials
  • Figure 11-3: HLE BiTE in Clinical Trials
  • Figure 12-1: BiTE Antibodies
  • Figure 12-2: Structure of CAR T-Cell
  • Figure 12-3: Comparison between Bite & CAR T-Cell
  • Figure 13-1: AMG420 - Clinical Trial Response of Patients
  • Figure 13-2: Clinical Trials for RRMM
  • Figure 13-3: AMG757 - Phase 1 Patient Response
  • Figure 13-4: AMG757 - Cytokine Release Syndrome in Patients
  • Figure 14-1: Favorable Parameters
  • Figure 14-2: Commercialization Challenges
  • Figure 15-1: Global - Cancer Immunotherapy Market Size (US$ Billion), 2020-2025
目次

"Global BiTE Antibodies Market, Price, Sales & Clinical Trials Insight 2025" Report Highlights:

  • Global BiTE Antibody Market Opportunity Insight (2021-2025)
  • Currently Only 1 BiTE Commercially Available In Market: Blinatumomab (Blincyto)
  • Blincyto Dosage & Market Sales Analysis ( Yearly, Quarterly & Regional Sales)
  • Global BiTE Antibody Clinical Trials Indicators by Phase, Company, Country, Indication & Patient Segment
  • Global Bispecific T-Cell Engagers Market Dynamics

The research report, "Global BiTE Antibodies Market , Price, Sales & Clinical Trials Insight 2025" reviews about the wide spread applications of the market and how it has been able to over-come the challenges that were widely distributed in the cancer therapeutics market for long period of time. The research report summarizes about the scientific advancement that has led to the amalgamation of applications of monoclonal antibodies into the bispecific cancer antibodies and making it widely acceptable against different types of cancer indications. It is analyzed that the great ongoing trends, opportunities and desirable achievements linked with the bispecific cancer antibody therapy market is set to deliver all the essential constructive applications in terms of healthcare benefits, thus making the market highly discussed cancer therapy in the current era of pharmaceutical industry.

The unique approach of BITE antibody market, widely known as bispecific cancer antibody market involves the innovative methodology of genetic engineering in order to develop an antibody that is able to target two different epitopes at similar time, making the entire cancer targeting process more accurate when compared with monoclonal therapy. Also, the association of the entire market with strong and robust clinical pipeline and research activities in the past as well as in present is believed to completely revolutionize the entire market opportunities held within bispecific cancer antibody market.

The next generation market opportunities held within the therapy with respect to healthcare benefits and making the therapy as a standard treatment regimen are estimated to cause a substantial rise in the market growth rate when compared with other cancer therapies. The large penetration of the bispecific cancer antibody drugs against different cancer indications is also leading to cause certain changes in the entire cancer market. Some of the parameters that are believed to be responsible for the market to be driven in the next few years are: increasing cases of cancer, arrival of innovative technologies, awareness of the applications of bispecific cancer antibody market and wide range of drugs available for different diseases.

As per "Global BiTE Antibodies Market, Price, Sales & Clinical Trials Insight 2025" report findings, it is observed that the entire market is linked with hundreds of high-performance drugs which have led to a decline in the global cancer mortality rate. The ease in the availability of the drugs and the innovative approach of increasing the target specificity are estimated to cause a radical shift in the overall acceptance of the market which was long ago observed for only some of the prominent cancer therapies such as chemotherapy. The entire market is observed to mature rapidly at global level as hundreds of bio-pharmaceutical companies and research centers are getting involved in the extension of the market by the approval of more potent drugs for commercial use. Some of the already pioneering leaders in the market is believed to be causing tremendous acceleration which is unmatchable and unimaginable for a therapy that has been discovered few decades ago. It is analyzed that the future terms of the market will make the market recognized as a standard and dominating treatment regimen for millions of patients.

Table of Contents

1. Bispecific Antibodies: The Next Generation Antibody Therapeutics

  • 1.1 History of Bispecific Antibodies
  • 1.2 Overview to Bispecific Antibodies

2. Advantages of Bispecific Antibody Over Monoclonal Antibody

3. BiTE (Bispecific T Cell Engager) - New Era in Cancer Immunotherapy

4. Structure & Design of BiTE

  • 4.1 Construction of Single Chain Variable Fragment Antibodies
  • 4.2 Bispecific scFv Antibody Expression & Production

5. BiTE Antibody - Mode of Action

  • 5.1 Redirected Target Cell Lysis by BiTE
  • 5.2 T-Cell Activation by BiTE
  • 5.3 Lytic Synapse Formation by BiTE

6. Blinatumomab (Blincyto): The First Approved BiTE Antibody

  • 6.1 Clinical Trials, Approval & Patenting
  • 6.2 Design & Mechanism of Action
  • 6.3 Adverse Drug Reactions & Management

7. Global BiTE Antibody Clinical Trials Indicators

  • 7.1 By Phase
  • 7.2 By Company
  • 7.3 By Country
  • 7.4 By Indication
  • 7.5 By Patient Segment

8. Global BiTE Clinical Pipeline By Company, Indication & Phase

  • 8.1 Preclinical
  • 8.2 Phase-I

9. Global BiTE Antibody Market Overview

  • 9.1 Current Market Scenario
  • 9.2 Blincyto Reimbursement Policy

10. Blincyto - Dosage & Market Sales Analysis

  • 10.1 Dosage of Blincyto in B-ALL
  • 10.2 Current Market Sales Analysis

11. Clinical Pipeline of Bispecific T-Cell Engagers

12. Bridging T-Cells to Tumors: CAR vs BiTEs

13. BiTE: Ongoing Research & Development

  • 13.1 BiTe Based Immunotherapy Treatment for Relapsed Refractory Multiple Myeloma
  • 13.2 Novel DLL3 Targeted BiTE shows Antitumor Activity in Small Cell Lung Cancer
  • 13.3 Preliminary Efficacy of AMG 160 in Metastatic Castration - Resistant Prostate Cancer

14. Global Bispecific T-Cell Engagers Market Dynamics

  • 14.1 Favorable Market Parameters
  • 14.2 Commercialization Challenges

15. Global BiTE Market Future Prospects

16. Competitive Landscape

  • 16.1 Amgen
  • 16.2 Bayers
  • 16.3 Micromet
  • 16.4 Psioxus Therapeutics
  • 16.5 Y Biologics
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.